Agoracom Blog Home

Posts Tagged ‘small cap’

« Older Entries
Newer Entries »

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:14 AM on Thursday, November 12th, 2020
kontrol-logo

Kontrol BioCloud a Safe Space Technology™

  • Received UL standards approval for its BioCloud® technology
  • As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
  • “We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

Field Certification was provided by ESAFE

Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: , , , , , , , , , , ,
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Else $BABY.ca $BABYF Launches a Nationwide Brand Campaign in the U.S.: “In an Else World” $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 7:22 AM on Thursday, November 12th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced the launch of its first National U.S. brand campaign, ‘In an Else World .’
  • Ahead of its nationwide retail launch in 380 stores across the U.S., the company has enlisted the global creative agency, Allenby Concept House and the award-winning Animation Director, Sivan Kidron to conceptualize the creative for the campaign
  • Click here to  view the full version video

VANCOUVER, BC , Nov. 12, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY.V) (OTC-QB: BABYF) ( Frankfurt : 0YL.F) (“Else” or the “Company”) the plant-based baby, toddler and children’s nutrition company , today announced the launch of its first National U.S. brand campaign, ‘In an Else World .’

Ahead of its nationwide retail launch in 380 stores across the U.S., the company has enlisted the global creative agency, Allenby Concept House and the award-winning Animation Director, Sivan Kidron to conceptualize the creative for the campaign. Click here to  view the full version video.

The campaign includes an interactive Instagram Live series with featured appearances from leading pediatricians, registered nurses and dietitians, including Kacie Barnes , MCN, RDN, LD and Hillary Sadler , MSN, RCN-OB, IBCLC as well as celebrity mom, Hilaria Baldwin . Tune into the series on Tuesdays at 1:00 p.m. EST , by following @elsenutrition on Instagram.

The campaign aims to spread Else Nutrition’s mission of providing real, plant-based and no-compromise nutrition alternatives for parents to feed their child, building the kind of world where families can choose nutrition that aligns with their values and needs.

Coming to life through bold and colorful animation, Else Nutrition welcomes all consumers to an ‘Else World’ where whole-food, plant-based nutrition is everywhere, especially in the baby aisle.  Focusing on the brand’s core values of providing natural products that are better for the baby, the parent and the planet, Else is excited to showcase its sustainable and cleaner offerings, including its first, breakthrough product – ‘Else Plant-Based Complete Nutrition for Toddlers’.

“We’re excited to launch our first, national marketing campaign. We’re inviting all parents to join us in building an Else World : the kind of world our babies and children deserve: with cleaner, less processed, whole-food plant-based nutrition, and a healthier planet. Since launching Else Nutrition we’ve seen how our ground-breaking plant-based nutrition has helped families around the U.S. provide their children with proper nutrition,” said Mrs. Hamutal Yitzhak , CEO and Co-Founder of Else Nutrition. “We believe that babies and children should have the same clean label, plant-based nutrition choices as their parents do, without compromise. We are excited to have the opportunity to increase awareness with consumers that will bring these ideals and values to life for millions of families across North America .”

“Together with the inspiring Else Nutrition team, we have created a world in which alternative possibilities are always available and all you need to do is to be open  to them,” said Sivan Kidron, Animation Director. “The animation plays on this idea, showing us what is behind and beyond what we currently see, while continuously opening our minds to new and exciting alternatives and innovations.”

Follow @elsenutrition on Instagram. Join an Else World on Instagram and Facebook by following #ElseWorld.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tags: , , , , , , , , ,
Posted in Else Nutrition Holdings Inc., Featured | Comments Off on Else $BABY.ca $BABYF Launches a Nationwide Brand Campaign in the U.S.: “In an Else World” $BYND $VERY.ca $INGR $VEGN $TOFB

Innocan $INNO.ca Enters Into Distribution Agreement to Sell its #CBD Derma Cosmetic Products in Germany $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 4:10 PM on Wednesday, November 11th, 2020
Innocan-Blog
  • Entered into a distribution agreement with iAmHealth Distribution UG, a CBD products provider in Germany to sell the Company’s SHIR Beauty and Relief & Go product lines in Germany.
  • iAmHealth will distribute Innocan’s unique cosmetic CBD products in Germany on a non-exclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties.
  • The parties intend to carry out the Agreement immediately following the completion of all registration and regulatory requirements in Germany.

Herzliya, Israel and Calgary, Alberta–(November 11, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Israel“) has entered into a distribution agreement dated 4, 2020 (the “Agreement“) with iAmHealth Distribution UG (“iAmHealth“), a CBD products provider in Germany to sell the Company’s SHIR Beauty and Relief & Go product lines in Germany.

Under the terms of the Agreement, iAmHealth will distribute Innocan’s unique cosmetic CBD products in Germany on a non-exclusive basis. The Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Agreement immediately following the completion of all registration and regulatory requirements in Germany.

Nina Wlodarczyk, iAmHealth’s Managing Director commented: “Our iAmHealth team comes from the medical industry with research based on science. As cannabidiol (“CBD”) became more available and gained popularity in Germany, we wanted to make our contribution and create a place for all of our existing customers, as well as people who are looking for new products they can trust, and with a high level of efficacy. We believe Innocan, as a pharmaceutical oriented company, is the perfect fit to complement the range of our existing products that we offer to the German consumer.”

Iris Bincovich, Innocan’s Founder and CEO, commented: “We are excited to start our product distribution in Germany. This is one of several distribution agreements that we have signed in Europe. I believe iAmHealth will provide a premier distribution channel for our SHIR and Relief & Go product lines.”

iAmHealth GmbH

iAmHealth Distribution UG, a subsidiary of iAmHealth GmbH (www.iam.health), is a collaborative group of multidisciplinary professionals from various sectors focusing on therapeutic formulations, including clinical trials, product development and manufacturing. iAmHealth has built a network of trustworthy Medical, R&D, Financial and Legal partners to supply and provide valuable expertise and extensive knowledge. iAmHealth is dedicated to the online distribution of various cosmetics and lifestyle products, utilizing an advanced, Artificial Intelligence driven e-commerce platform, enabling complete efficacy and security to a wide range of end consumers. iAmHealth strives to offer the very best cosmetics, natural products and CBD, which are highly trustworthy and proven, at reasonable prices, which support and increase the well-being of its customers.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Israel, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining CBD with other products. Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. The Company plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Enters Into Distribution Agreement to Sell its #CBD Derma Cosmetic Products in Germany $CGC.ca $APHA $OVAT.ca $KHRN.ca

VIDEO – PyroGenesis $PYR.ca Discusses $12M Raise And Impending Uplist To TSX $RTN $NOC $UTX $DDD.ca $HPQ.ca

Posted by AGORACOM-JC at 9:00 AM on Wednesday, November 11th, 2020

Peter Pascali sits down with AGORACOM to discuss the significance of the Company’s recently closed $12,000,000 financing and its implications on the future of PyroGenesis, including: 

  • The impending uplist to the TSX big board
  • Potential spin-outs
  • Reasons for raising more funds than “needed”
  • What role, if any, potential Iron Ore Pelletization contracts played in the financing

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, Featured, PyroGenesis Canada Inc. | Comments Off on VIDEO – PyroGenesis $PYR.ca Discusses $12M Raise And Impending Uplist To TSX $RTN $NOC $UTX $DDD.ca $HPQ.ca

PyroGenesis $PYR.ca Announces Closing of $12 Million Bought-Deal Prospectus Offering of Units, Including Full Exercise of the Over-Allotment Option $RTN $NOC $UTX $DDD.ca $HPQ.ca

Posted by AGORACOM-JC at 9:11 AM on Tuesday, November 10th, 2020
  • Further to its press release dated November 3, 2020, the closing of its bought-deal short form prospectus offering pursuant to which the Company issued 3,354,550 units of the Company (at a price of $3.60 per Unit for aggregate gross proceeds of $12,076,380 (the “ Offering ”), including the full exercise of the over-allotment option
  • The Offering was led by Mackie Research Capital Corporation, as sole underwriter and sole bookrunner
  • Net proceeds from the Offering will be used for working capital and other purposes as described in the prospectus of the Company dated November 3, 2020 prepared in connection with the Offering.

MONTREAL, Nov. 10, 2020 — PyroGenesis Canada Inc. (“ PyroGenesis ” or the “ Company ”) (TSXV:PYR) (OTCQB:PYRNF) (FRA:8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and products, is pleased to announce, further to its press release dated November 3, 2020, the closing of its bought-deal short form prospectus offering pursuant to which the Company issued 3,354,550 units of the Company (the “ Units ”) at a price of $3.60 per Unit for aggregate gross proceeds of $12,076,380 (the “ Offering ”), including the full exercise of the over-allotment option. The Offering was led by Mackie Research Capital Corporation, as sole underwriter and sole bookrunner, (the “ Underwriter ”).

Each Unit is comprised of one common share of the Company (a ” Common Share “) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a ” Warrant “). Each Warrant entitles the holder thereof to purchase one additional Common Share at an exercise price of $4.50 for a period of 24 months from the closing of the Offering.

Provided that if, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “ Exchange ”), or other principal exchange on which the Common Shares are listed, is greater than $6.75 for 20 consecutive trading days, the Company may, within 15 days of the occurrence of such event, deliver a notice to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice (the “ Accelerated Exercise Period ”). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.

The net proceeds from the Offering will be used for working capital and other purposes as described in the prospectus of the Company dated November 3, 2020 prepared in connection with the Offering.

In consideration for the services provided by the Underwriter, the Company has paid a cash commission equal to 6.5% of the gross proceeds of the Offering and issued to the Underwriter an aggregate of 191,414 non-transferable compensation options, which are exercisable into Units at a price of $3.60 per Unit at any time up to 24 months from closing of the Offering.

About PyroGenesis Canada Inc.  

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com . 

For further information, please contact:  

Rodayna Kafal, Vice President, Investor Relations and Strategic Business Development, 

Phone: (514) 937-0002, 

E-mail: [email protected] 

RELATED LINK: http://www.pyrogenesis.com/  

Cautionary Note Regarding Forward Looking Information:  

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the intended use of the proceeds of the Offering. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, including under “Risk Factors” in the Company’s most recent annual information form, which filings can be found under the Company’s profile at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Toronto Stock Exchange nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Announces Closing of $12 Million Bought-Deal Prospectus Offering of Units, Including Full Exercise of the Over-Allotment Option $RTN $NOC $UTX $DDD.ca $HPQ.ca

Hollister Biosciences $HOLL.ca $HSTRF Launches Direct to Consumer Cannabis Delivery Platform, Dreamy Delivery $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:15 AM on Tuesday, November 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery
  • Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020
  • Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide

VANCOUVER, BC , Nov. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery (” Dreamy ” or the ” Platform “).

The company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California ( “Bay Area “), to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the Bay Area. The Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide.

Carl Saling , CEO of Hollister , shared: “This is a major first step in our quest to be the dominant direct to consumer platform delivering cannabis to the entire state of California .”

Website: www.dreamydelivery.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com .

Tags: , , , , , , , , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca $HSTRF Launches Direct to Consumer Cannabis Delivery Platform, Dreamy Delivery $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 4:23 PM on Monday, November 9th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in 280 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” … and if that is all they had you would have the makings of a great small cap cannabis company. 

But there is more …. way more. 

Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona.  More than just lip service:

  • Venom just surpassed $30,000,000 (MILLION) in revenue YEAR TO DATE
  • Venom Extracts is one of Arizona’s premier extract brands 
  • One of the state’s largest producers of medical cannabis distillate and related products
  • The products are award winning
  • ….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen  

THE NUMBERS SAY IT ALL 

1.  RECORD Q3 REVENUE          $12.5M 

2.  CRAZY REVENUE GROWTH    5,200%

3.  RECORD EBITDA                 $1.265M (vs a loss of $362,000) In case you’re wondering if this was a fluke quarter, this is what Q2 looked like: 

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

HOLLISTER HEADED TOWARDS $50,000,000 REVENUE? 

If you’re paying attention, HOLL is achieving enormous growth both year over year and sequentially.  If we extrapolate the latest Q3 numbers, Hollister is on a $50,000,000 annualized revenue run rate assuming no further growth. 

But there is more. 

The State of Arizona just approved recreational cannabis in Arizona.  This is a potential windfall for Venom given the fact its brand, reputation and dispensary penetration from its award winning medical cannabis is about as good as it gets.  How good is Hollister now? 

How good does it get? 

Watch this incredible interview with Venom Extracts Founder Jake Cohen, the coolest exec in small cap cannabis because he delivers incredible results with sweat, swagger and great swag to boot.  

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: , , , , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Hollister Biosciences | Comments Off on VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Empower Clinics $CBDT.ca Announces Closing of $1.228 Million Private Placement Financing and Insider Subscription $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 3:59 PM on Monday, November 9th, 2020
  • Closed its previously announced private placement of units of the Company, which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit for aggregate gross proceeds of $1,228,356.55
  • The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner

VANCOUVER, BC / November 9, 2020 / Empower Clinics Inc. (“Empower” or the “Company“) (CSE:CBDT), is pleased to announce that it has closed its previously announced private placement of units of the Company (the “Units“), which included the exercise of an over-allotment option, pursuant to which the Company issued 24,567,131 Units at a price of $0.05 per Unit (the “Offering Price“) for aggregate gross proceeds of $1,228,356.55 (the “Offering“). The Offering was led by Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“).

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“), with each Warrant exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.

The Company is also pleased to announce that Steven McAuley, the Chief Executive Officer a director of the Company, participated in the Offering by subscribing for 1,200,000 Units for $60,000.

The Company intends to use the net proceeds raised under the Offering to support the objective of clinic growth, lab testing services, sales and marketing, for general working capital purposes.

In connection with the Offering, the Agent received an aggregate cash fee of $88,000. In addition, the Company granted the Agent compensation options (the “Compensation Options“) exercisable for 1,760,000 Units at an exercise price equal to the Offering Price for a period of 24 months following the closing of the Offering.

The subscription by Mr. McAuley is deemed, “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation requirements of MI 61-101 since none of the securities of the Company are listed on a stock exchange specified in section 5.5(b) thereof. The transaction is exempt from the minority shareholder approval requirements of MI 61-101 since, at the time the transaction was agreed to, neither the fair market value of the transaction nor the fair market value of the consideration for the transaction, insofar as it involves interested parties, exceeded 25% of the Company’s market capitalization.

The securities issued pursuant to the Offering will be subject to a four-month hold period under applicable securities laws in Canada.

In connection with the Offering, $18,356.55 of the subscription funds are a result of a settlement with an arm’s length service provider of through the issuance of 367,131 Units.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with an expanded suite of physician-based services. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability and will lead our diagnostic and scientific advancement.

ON BEHALF OF THE BOARD OF DIRECTORS

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces Closing of $1.228 Million Private Placement Financing and Insider Subscription $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Harborside Inc. $HBOR Announces Cultivation Facility Upgrades and Launch of Clones Sales at All Harborside Retail Stores $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 8:28 AM on Friday, November 6th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564690/hub/Harborside_Inc2_logo.png

OAKLAND, Calif. and TORONTO, Nov. 6, 2020 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced today that it is engaging in a substantial upgrade of one of its approximately 45,000 square foot greenhouses at its 47-acre integrated production campus in Salinas, California (the “Salinas Facility”).

The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights in the greenhouse. Following the successful completion of these upgrades, on an annualized basis. the Company expects an approximately 50% increase in production from this greenhouse, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity of the Salinas Facility. The project is expected to be completed within the first quarter of 2021 and the Company expects that the total cost of the updates will be fully recouped within the first twelve months of operation following completion of the project.

In addition, the Company announced today that its in-house brand, Harborside Farms, a highly recognized, customer-centric product line, will commence sales of clones grown at its Salinas Facility at all Harborside branded locations, including Desert Hot Springs. On a year-over-year basis, sales of Harborside Farms products have grown by 229% at Harborside’s iconic dispensaries capturing 42% of its total retail flower sales through the end of the third quarter of 2020, demonstrating continuing strength and customer loyalty to one of its flagship brands.

“We have carved out a strong reputation for supplying high-quality cannabis products to the growing California market and these upgrades are a crucial investment that will fuel our growth heading into 2021,” said Peter Bilodeau, Interim CEO and Chairman of Harborside. “Leveraging the strength of our Salinas facility, we’re thrilled to be officially commencing sales of clones that are grown at our farm and only available at our stores immediately. This new in-house product category was developed utilizing sustainable cultivation techniques to provide discerning consumers with access to locally grown, high-quality cannabis.”

The Company’s clone initiative aims to capitalize on these trends and the continued high-quality production from its Salinas Facility, and will underscore the single-source, local nature of the Harborside Farms brand, as well as its emphasis on sustainable cultivation practices. The initiative will also continue to enhance the Company’s retail gross margins by adding an additional in-house product category sourced internally from its Salinas Facility.

At its retail dispensaries, clones (inclusive of seeds and seedlings) are expected to comprise approximately 5% of the Company’s total annual retail sales, or approximately $2M in annual net retail revenue in 2020. The Company’s average gross margin in this category is approximately 52% through the end of the third quarter. The Company anticipates Harborside Farms clones capturing at least 50% of total clone sales throughout the course of 2021, resulting in total sales of approximately $1M, with estimated gross margins as high as 90%. The Company expects average gross margins across its entire clones category to increase to approximately 70% during 2021 as a result of this initiative, providing an approximate 18% improvement over its expected annual average gross margin in this category as compared to 2020.

For the latest news, activities, and media coverage, please visit the Harborside corporate website at http://www.investharborside.com or connect with us on LinkedIn, Facebook, and Twitter.

About Harborside:
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.

Tags: , , , , , , , ,
Posted in All Recent Posts, Harborside | Comments Off on Harborside Inc. $HBOR Announces Cultivation Facility Upgrades and Launch of Clones Sales at All Harborside Retail Stores $VFF.to $HARV.ca $ACB.to

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives CSA Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 1:54 PM on Thursday, November 5th, 2020
kontrol-logo

 Kontrol BioCloud® a Safe Space Technology™ –

  • Announced that it has received CSA standards approval for its BioCloud® technology
  • “This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol
  • CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety

TORONTO, ON / ACCESSWIRE / November 5, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

Field Certification was provided by ESAFE

CSA regulations require manufacturers of products sold in Canada to receive CSA Standards approval for electrical safety. The field evaluation process follows the CSA’s SPE-1000 standard, which has three mandatory and non-destructive tests. Upon successful inspection, ESAFE validates the equipment meets CSA’s SPE-1000 standards and labels it approved. ESAFE’s labels are recognized across Canada under the Standards Council of Canada accreditation program.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com.

Image: https://www.accesswire.com/users/newswire/images//10252018KNR2.pngImage: https://www.accesswire.com/users/newswire/images//10252018KNR3.pngImage: https://www.accesswire.com/users/newswire/images//10252018KNR4.png

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud® Analyzer are subject to the risk that the Kontrol BioCloud® Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives CSA Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

« Older Entries
Newer Entries »